[go: up one dir, main page]

AU2002349784A1 - Nf-kappab activating genes - Google Patents

Nf-kappab activating genes

Info

Publication number
AU2002349784A1
AU2002349784A1 AU2002349784A AU2002349784A AU2002349784A1 AU 2002349784 A1 AU2002349784 A1 AU 2002349784A1 AU 2002349784 A AU2002349784 A AU 2002349784A AU 2002349784 A AU2002349784 A AU 2002349784A AU 2002349784 A1 AU2002349784 A1 AU 2002349784A1
Authority
AU
Australia
Prior art keywords
activating genes
kappab
kappab activating
genes
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002349784A
Other versions
AU2002349784A8 (en
Inventor
Akio Matsuda
Shuji Muramatsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Original Assignee
Asahi Kasei Corp
Asahi Chemical Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2001368692A external-priority patent/JP2006166701A/en
Priority claimed from JP2002291302A external-priority patent/JP2006166705A/en
Application filed by Asahi Kasei Corp, Asahi Chemical Industry Co Ltd filed Critical Asahi Kasei Corp
Publication of AU2002349784A1 publication Critical patent/AU2002349784A1/en
Publication of AU2002349784A8 publication Critical patent/AU2002349784A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2002349784A 2001-12-03 2002-12-03 Nf-kappab activating genes Abandoned AU2002349784A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2001368692A JP2006166701A (en) 2001-12-03 2001-12-03 NF-κB activating gene
JP2001-368692 2001-12-03
US33582901P 2001-12-05 2001-12-05
US60/335,829 2001-12-05
JP2002291302A JP2006166705A (en) 2002-10-03 2002-10-03 NF-kappaB ACTIVATING GENE
JP2002-291302 2002-10-03
US41576902P 2002-10-04 2002-10-04
US60/415,769 2002-10-04
PCT/JP2002/012644 WO2003048202A2 (en) 2001-12-03 2002-12-03 Nf-kappab activating genes

Publications (2)

Publication Number Publication Date
AU2002349784A1 true AU2002349784A1 (en) 2003-06-17
AU2002349784A8 AU2002349784A8 (en) 2003-06-17

Family

ID=27482716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002349784A Abandoned AU2002349784A1 (en) 2001-12-03 2002-12-03 Nf-kappab activating genes

Country Status (2)

Country Link
AU (1) AU2002349784A1 (en)
WO (1) WO2003048202A2 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
AU2003245990A1 (en) * 2002-06-26 2004-01-19 Bayer Healthcare Ag Regulation of human map kinase kinase kinase
WO2004038373A2 (en) * 2002-10-22 2004-05-06 Oregon Health And Science University Apoptotic response regulation through interaction of tripartite motif protein 32 with pias
AU2003290432A1 (en) * 2002-12-26 2004-07-22 Asahi Kasei Pharma Corporation T cell activating gene
WO2004106937A2 (en) * 2003-06-02 2004-12-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled p2y purinoreceptor 6 (p2y6)
EP1636258A2 (en) * 2003-06-10 2006-03-22 Xantos Biomedicine AG Angiogenic factor and inhibitors thereof
NZ547633A (en) 2003-11-06 2010-08-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (en) 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates
JP2007054042A (en) * 2005-07-26 2007-03-08 Japan Science & Technology Agency Interferon derived molecule IPS-1
EP2324044A4 (en) * 2008-08-04 2012-04-25 Univ Miami STING (INTERFERON GENE STIMULATOR), A REGULATOR OF INDIAN IMMUNE RESPONSES
US20110212111A1 (en) * 2008-11-04 2011-09-01 Cambier John C MHC II Associated Protein and Uses Thereof
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
EP2528625B1 (en) 2010-04-15 2013-07-10 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
JP2013534520A (en) 2010-06-08 2013-09-05 ジェネンテック， インコーポレイテッド Cysteine engineered antibodies and conjugates
CN103313990B (en) 2010-11-17 2016-07-20 基因泰克公司 Alanyl maytansinol antibody coupling matter
CN103608684B (en) 2011-05-12 2016-05-04 基因泰克公司 A Multiple Reaction Monitoring LC-MS/MS Method for the Detection of Therapeutic Antibodies in Animal Samples Using Framework Signature Peptides
CN103030688B (en) * 2011-09-30 2014-09-17 北京大学 Short chain polypeptide for inhibiting cancer cell growth as well as encoding gene and application of short chain polypeptide
RS54446B1 (en) 2011-10-14 2016-06-30 Medimmune Limited PIROLOBENZIDIAZEPINE AND ITS CONJUGATES
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
PT2906251T (en) 2012-10-12 2017-12-04 Medimmune Ltd CONJUGATES OF PYRROLOBENZODIAZEPINA-ANTIBODY ANTI-CD22
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
JP6270859B2 (en) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ Pyrrolobenzodiazepine-antibody conjugate
ES2530968T3 (en) 2012-10-12 2015-03-09 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
TR201808051T4 (en) 2012-10-12 2018-06-21 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates.
CA2887895C (en) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd19 antibody conjugates
EA032986B1 (en) 2012-12-21 2019-08-30 Медимьюн Лимитед Pyrrolobenzodiazepines
CA2894961C (en) 2012-12-21 2020-09-15 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
CA2904044C (en) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3033111B1 (en) 2013-08-12 2019-03-13 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
JP6671292B2 (en) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド Peptidomimetic compounds and antibody-drug conjugates thereof
MX2016007578A (en) 2013-12-16 2016-10-03 Genentech Inc 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
BR112016013861A2 (en) 2013-12-16 2017-10-10 Genentech Inc drug and antibody conjugates, compounds, treatment method and pharmaceutical composition
JP6531166B2 (en) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugate
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
JP6622293B2 (en) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド Anthracycline disulfide intermediates, antibody-drug conjugates, and methods
PE20170905A1 (en) 2014-09-17 2017-07-12 Genentech Inc PYROLOBENZODIAZEPINES AND ANTIBODY-DISULFIDE CONJUGATES THEREOF
JP6878287B2 (en) 2014-11-25 2021-05-26 アーデーセー セラピューティクス ソシエテ アノニム Pyrrolobenzodiazepine-antibody conjugate
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN109476648B (en) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 Sevelamer antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
SG11201906969PA (en) 2017-02-01 2019-08-27 Modernatx Inc Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
ES2871001T3 (en) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugates of pyrrolobenzodiazepines and antibodies
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
KR102189731B1 (en) 2017-04-18 2020-12-11 메드임뮨 리미티드 Pyrrolobenzodiazepine conjugate
MX2019012464A (en) 2017-04-20 2019-12-11 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate.
BR112019026564A2 (en) 2017-06-14 2020-06-30 Adc Therapeutics Sa dosing regimens for administration of an anti-cd19 adc
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP7708662B2 (en) 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Conjugated chemical degraders and methods of use
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
KR102890251B1 (en) 2019-03-15 2025-11-25 메드임뮨 리미티드 Azetidobenzodiazepine dimers and conjugates comprising the same for use in the treatment of cancer
CA3162386A1 (en) 2019-12-18 2021-06-24 Glen N. Barber Substituted 1,2, 4-triazoles and methods of use
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
TW202432187A (en) 2022-12-23 2024-08-16 美商建南德克公司 Cereblon degrader conjugates, and uses thereof
CN121263210A (en) 2023-04-17 2026-01-02 沛科生物公司 Antibodies and antibody-drug conjugates, as well as their usage, synthesis processes, and intermediates
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4311835A1 (en) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Method for inhibiting gene transcription
GB9424497D0 (en) * 1994-12-05 1995-01-25 Karobio Ab Reporter cell line
US5932425A (en) * 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
JPH11266872A (en) * 1998-03-20 1999-10-05 Suntory Ltd Screening of substance suppressing activation of nf-kappa b
SE0001071D0 (en) * 2000-03-27 2000-03-27 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines

Also Published As

Publication number Publication date
WO2003048202A2 (en) 2003-06-12
WO2003048202A3 (en) 2004-07-01
AU2002349784A8 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
AU2002349784A1 (en) Nf-kappab activating genes
AU2002313559A1 (en) Genes
EP1247815A3 (en) Modified oligonucleotides and uses thereof
AU2002357860A1 (en) Enzymes
AU2002347778A1 (en) Enzymes
AU2001264247A1 (en) GASC1 gene
AU2001240103A1 (en) Reproduction-specific genes
AU2001247444A1 (en) Erbeta-mediated gene expression
AU2001285743A1 (en) Adipose-related gene
AU2002257273A1 (en) Enzymes
AU2002226571A1 (en) Biligands
AU2001100406A4 (en) DriverSMS
AUPR482001A0 (en) Metal-handling enzymes
AU2002328863A1 (en) Oncosuppressive gene
AU2002210985A1 (en) Pca2501 gene
AUPR232800A0 (en) Gene expression
AU2002308879A1 (en) Stat6-activating genes
AU2002257925A1 (en) Numberplates
AU2002337325A1 (en) Gene expression
HK1060579A (en) Oncosuppressive gene
AU2002343924A1 (en) Hepnadc gene
HK1063063A (en) Improved gene expression
AU2001100214A4 (en) Dolly-trolley
AU2001100338A4 (en) Sunglove
AU2002100746A4 (en) Adrail

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase